The University of Chicago Header Logo

Connection

John Beshai to Humans

Back to Details
This is a "connection" page, showing publications John Beshai has written about Humans.
John Beshai
Connection Strength
0.247
Humans
  1. Drug-Induced QTc Prolongation. Am J Cardiol. 2017 01 15; 119(2):280-283.
    View in: PubMed
    Score: 0.018
  2. Cardiac sarcoidosis detected by late gadolinium enhancement and prevalence of atrial arrhythmias. Am J Cardiol. 2014 May 01; 113(9):1556-60.
    View in: PubMed
    Score: 0.015
  3. Cardiac sarcoidosis and coronary artery disease: a two-hit mechanism to left ventricular dysfunction (or is it)? Sarcoidosis Vasc Diffuse Lung Dis. 2013 Nov 25; 30(3):237-40.
    View in: PubMed
    Score: 0.015
  4. Effect of defibrillation threshold testing-induced ventricular fibrillation on renal function. J Interv Card Electrophysiol. 2013 Dec; 38(3):209-15.
    View in: PubMed
    Score: 0.015
  5. Reply to the editor-out of service lead. Heart Rhythm. 2013 May; 10(5):e68-9.
    View in: PubMed
    Score: 0.014
  6. Out-of-service lead: abnormal presentation at follow-up. Heart Rhythm. 2013 Jan; 10(1):144-6.
    View in: PubMed
    Score: 0.014
  7. Myocardial damage in patients with sarcoidosis and preserved left ventricular systolic function: an observational study. Eur J Heart Fail. 2011 Nov; 13(11):1231-7.
    View in: PubMed
    Score: 0.013
  8. Role of echocardiography in selection of patients for biventricular pacing therapy. Curr Cardiol Rep. 2009 Sep; 11(5):352-9.
    View in: PubMed
    Score: 0.011
  9. Mechanical dyssynchrony from the perspective of a cardiac electrophysiologist. Curr Opin Cardiol. 2008 Sep; 23(5):447-51.
    View in: PubMed
    Score: 0.010
  10. Cardiac-resynchronization therapy in heart failure with narrow QRS complexes. N Engl J Med. 2007 Dec 13; 357(24):2461-71.
    View in: PubMed
    Score: 0.010
  11. The resynchronization therapy in narrow QRS study (RethinQ study): methods and protocol design. J Interv Card Electrophysiol. 2007 Sep; 19(3):149-55.
    View in: PubMed
    Score: 0.010
  12. Marker annotation misalignment on a defibrillator interrogation printout. J Cardiovasc Electrophysiol. 2007 Nov; 18(11):1216-7.
    View in: PubMed
    Score: 0.010
  13. Development of a biomarker panel to predict cardiac resynchronization therapy response: Results from the SMART-AV trial. Heart Rhythm. 2019 05; 16(5):743-753.
    View in: PubMed
    Score: 0.005
  14. Improved detection of myocardial damage in sarcoidosis using longitudinal strain in patients with preserved left ventricular ejection fraction. Echocardiography. 2016 Sep; 33(9):1344-52.
    View in: PubMed
    Score: 0.005
  15. Cost-effectiveness of implantable cardiac devices in patients with systolic heart failure. Heart. 2016 11 01; 102(21):1742-1749.
    View in: PubMed
    Score: 0.005
  16. Long-Term Success of Irrigated Radiofrequency Catheter Ablation of Sustained Ventricular Tachycardia: Post-Approval THERMOCOOL VT Trial. J Am Coll Cardiol. 2016 Feb 16; 67(6):674-683.
    View in: PubMed
    Score: 0.004
  17. Prognosis of Myocardial Damage in Sarcoidosis Patients With Preserved Left Ventricular Ejection Fraction: Risk Stratification Using Cardiovascular Magnetic Resonance. Circ Cardiovasc Imaging. 2016 Jan; 9(1):e003738.
    View in: PubMed
    Score: 0.004
  18. Individual patient data network meta-analysis of mortality effects of implantable cardiac devices. Heart. 2015 Nov; 101(22):1800-6.
    View in: PubMed
    Score: 0.004
  19. Hybrid atrial fibrillation ablations and the increasing importance of the hybrid cardiovascular laboratory operating room. Ann Card Anaesth. 2015 Jul-Sep; 18(3):286-9.
    View in: PubMed
    Score: 0.004
  20. Impact of baseline PR interval on cardiac resynchronization therapy outcomes in patients with narrow QRS complexes: an analysis of the ReThinQ Trial. J Interv Card Electrophysiol. 2015 Aug; 43(2):145-9.
    View in: PubMed
    Score: 0.004
  21. Heart Rythm Society expert consensus statement on electrophysiology laboratory standards: process, protocols, equipment, personnel, and safety. Heart Rhythm. 2014 Aug; 11(8):e9-51.
    View in: PubMed
    Score: 0.004
  22. ICD lead parameters, performance, and adverse events following continuous-flow LVAD implantation. Pacing Clin Electrophysiol. 2014 Apr; 37(4):464-72.
    View in: PubMed
    Score: 0.004
  23. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Europace. 2012 Sep; 14(9):1236-86.
    View in: PubMed
    Score: 0.003
  24. 2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management. Heart Rhythm. 2012 Sep; 9(9):1524-76.
    View in: PubMed
    Score: 0.003
  25. HRS/ACCF expert consensus statement on pacemaker device and mode selection. Developed in partnership between the Heart Rhythm Society (HRS) and the American College of Cardiology Foundation (ACCF) and in collaboration with the Society of Thoracic Surgeons. Heart Rhythm. 2012 Aug; 9(8):1344-65.
    View in: PubMed
    Score: 0.003
  26. HRS/ACCF expert consensus statement on pacemaker device and mode selection. J Am Coll Cardiol. 2012 Aug 14; 60(7):682-703.
    View in: PubMed
    Score: 0.003
  27. Implantable cardioverter defibrillator therapy in patients with cardiac sarcoidosis. J Cardiovasc Electrophysiol. 2012 Sep; 23(9):925-9.
    View in: PubMed
    Score: 0.003
  28. Medtronic Sprint Fidelis lead recall: determining the initial 5-year management cost to Medicare. Heart Rhythm. 2011 Aug; 8(8):1192-7.
    View in: PubMed
    Score: 0.003
  29. Use of a primary prevention totally subcutaneous defibrillator in hypertrophic cardiomyopathy. Circ Arrhythm Electrophysiol. 2010 Oct; 3(5):560-1.
    View in: PubMed
    Score: 0.003
  30. Ranolazine safely decreases ventricular and atrial fibrillation in Timothy syndrome (LQT8). Pacing Clin Electrophysiol. 2012 Mar; 35(3):e62-4.
    View in: PubMed
    Score: 0.003
  31. Late potential at the high ventricular septal level in a patient with Brugada: possible mechanisms and clinical implications. J Electrocardiol. 2010 Sep-Oct; 43(5):459-62.
    View in: PubMed
    Score: 0.003
  32. Oscillatory breathing and exercise gas exchange abnormalities prognosticate early mortality and morbidity in heart failure. J Am Coll Cardiol. 2010 Apr 27; 55(17):1814-23.
    View in: PubMed
    Score: 0.003
  33. Initial experience using a radiofrequency powered transseptal needle. J Cardiovasc Electrophysiol. 2010 Apr; 21(4):423-7.
    View in: PubMed
    Score: 0.003
  34. Can real-time three-dimensional echocardiography be used reliably for the assessment of left ventricular dyssynchrony? Arch Cardiovasc Dis. 2009 Jun-Jul; 102(6-7):469-72.
    View in: PubMed
    Score: 0.003
  35. Lipid-lowering drug use is associated with reduced prevalence of atrial fibrillation in patients with left ventricular systolic dysfunction. Heart Rhythm. 2006 Aug; 3(8):881-6.
    View in: PubMed
    Score: 0.002
  36. The relationship between stature and the prevalence of atrial fibrillation in patients with left ventricular dysfunction. J Am Coll Cardiol. 2006 Apr 18; 47(8):1683-8.
    View in: PubMed
    Score: 0.002
  37. Renal insufficiency and the risk of infection from pacemaker or defibrillator surgery. Pacing Clin Electrophysiol. 2006 Feb; 29(2):142-5.
    View in: PubMed
    Score: 0.002
  38. Alcohol septal ablation complicated by complete heart block and permanent pacemaker failure. Catheter Cardiovasc Interv. 2003 Feb; 58(2):189-93.
    View in: PubMed
    Score: 0.002
  39. Predicting post-coronary bypass surgery atrial arrhythmias from the preoperative electrocardiogram. Am Heart J. 2001 Nov; 142(5):806-10.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.